BIO continues to pump, can the longevity AI agent help revive DeSci?

Written by: Nicky, Foresight News

The token BIO of Bio Protocol has recently performed impressively. According to data from Bitget, the price of BIO started at $0.056 on August 6, 2025, and rose to a peak of $0.2081 on August 22, with an increase of over 270% during this period.

Currently, the staking scale of BIO has reached approximately 174 million coins, accounting for about 9.3% of the total circulation of 1.854 billion coins. At the same time, BIO has been listed on several mainstream exchanges, including Binance, Coinbase, Bithumb, and others.

At the end of 2024, the DeSci craze lasted only a few months. After BIO was listed on Binance, its token performance can only be described as “disastrous.” After reaching a historical high of $0.8 shortly after launch, it continued to decline. By August 2025, the token price hovered around $0.05, having dropped more than 90% from its historical peak. So what exactly caused BIO to come back to life?

Tracing back to the project’s origin, on November 8, 2024, Binance Labs (now YZi Labs) announced an investment in Bio Protocol. Although the investment details have not been disclosed, this move signifies mainstream capital’s recognition of the DeSci sector.

As a representative project in the DeSci track, Bio Protocol’s core goal is to “transform the funding and commercialization model of early biotechnology research” and build a network of biotechnology DAOs.

By leveraging blockchain technology, global scientists, patients, and investors can collaboratively participate in new drug development, addressing the pain points of traditional research where “funding is concentrated in large pharmaceutical companies and results are closed off.” This helps global participants fund and co-participate in the development of new drugs, particularly targeting issues related to rare diseases, longevity research, and emerging health concerns.

On June 3, 2025, the DeSci project token PYTHIA started to rise, continuously increasing from $0.0168 to $0.122 on August 14, with a growth rate of 626%.

On July 31, 2025, Coinbase launched two DeSci project tokens, BIO and RSC, marking the return of DeSci to the view of the mainstream digital currency market in the West.

Since then, the token VITA of the DeSci project VitaDAO has continued to rise from $1.17 on August 1 to a peak of $2.22 on August 22, with a total increase of 89%. The token NEURON of Cerebrum DAO also performed well in August, with an increase of over 180% this month. Meanwhile, the token CRYO of CryoDAO saw an increase of over 200% this month, the token GROW of ValleyDAO rose by 76% this month, and the token HAIR of HairDAO increased by 67.5% this month. It can be seen that DeSci is on the rise.

Aubrai: How AI Scientists Are Redefining the Rules of Longevity Research?

Entering 2025, Bio Protocol accelerates iteration. On August 21, Bio Protocol, in collaboration with VitaDAO, launched its first BioAgent Launch project, Aubrai, marking the official implementation of its “decentralized scientific agency” program. This sale lasted only 24 hours, with users participating by staking BioXP and investing in BIO tokens, and the TGE for the AUBRAI token will take place on August 25.

The tokenomics of AUBRAI has been announced, with a total supply of 2 million tokens. The token distribution is as follows: 20% for sale, 6% for the liquidity pool, 15% for the treasury, 20.1% allocated to initial backers, 10% for the LEV Foundation, 22% for VitaDAO, and 6.9% for Bio Protocol.

Aubrai is derived from the private laboratory data of longevity research pioneer Dr. Aubrey de Grey, who proposed the “Strategies for Engineered Negligible Senescence” (SENS) aimed at preventing age-related diseases by repairing the damage to aging cells in the human body. He holds a Bachelor’s degree in Computer Science and a PhD in Biology from Cambridge University, and has authored works such as “Mitochondrial Free Radical Aging Theory” (1999) and “Ending Aging” (2007).

de Grey is currently the Chairman and Chief Science Officer of the LEV Foundation. The foundation focuses on longevity research, with its flagship project “Robust Mouse Rejuvenation” testing combinations of late-stage intervention therapies through large-scale mouse lifespan experiments. These experiments are conducted in collaboration with Ichor Life Sciences, emphasizing damage repair methods and avoiding early interventions such as gene modification, in order to accelerate clinical translation to humans.

Another LEV project “Transplants on Demand” explores tissue engineering and funds Keinice Bio’s cryopreservation technology, using ultra-cold helium to achieve organ vitrification preservation. This avoids the toxicity issues associated with traditional cryoprotectants, aiming to provide “ready-to-use” young organ replacements to address organ failure caused by aging.

The LEV Foundation also supports the Alliance for Longevity Initiatives, a 501©(4) non-profit organization aimed at promoting government policy support for longevity research in the United States. By collaborating with relevant experts, it seeks to raise public awareness of age-related chronic diseases and advocate for national funding.

Through these studies, its private laboratory has accumulated thousands of unpublished research notes, internal experimental data, and collective knowledge in the global longevity field. These “private scientific research assets,” which were previously limited to the core team, are now integrated by Aubrai as training data.

In practical applications, Aubrai has transformed the workflow of the de Grey team. It manages over a dozen complex longevity studies, compressing manual reviews that originally took weeks into just a few days. It also identifies dose conflicts, timing mismatches, and hidden biases, and even uncovers new issues that the team had not noticed.

According to the official roadmap, Aubrai has currently received joint funding from Bio Protocol and VitaDAO for the RMR2 pilot study, aimed at validating candidate interventions and optimizing delivery methods; community scientists can experience their collaborative capabilities as “co-scientists” through the closed beta version of the CHAT UI. At the same time, the wallet supports a self-hosted EOA wallet built on the Coinbase Developer Platform, with limited transaction authorization capabilities.

In future plans, Aubrai will launch a semi-autonomous agent in Q4 2025 (integrating Base AgentKit, supporting full trade execution and financial autonomy), and open the FAILURE DB database (which records negative outcomes and design flaws to avoid repeated mistakes), ultimately achieving “fully autonomous research” — a complete scientific output process from hypothesis generation, experimental design to wet lab execution and paper publication.

V2 Upgrade: Building an Efficient Cycle of “Research - Capital”

The landing of Aubrai relies on the support of the Bio Protocol V2 version. Its V2 version adopts the “launch and grow” concept, achieving sustainable growth through a community-driven launchpad:

Undervalued Launch: Referencing platforms like Pump.fun, the initial valuation of the project has dropped to an FDV of $205,000, with 37.5% of the tokens sold directly, and each user can subscribe to a maximum of 0.5% of the total tokens for sale.

Sustainable Liquidity: All funds raised after the launch (BIO tokens) will automatically generate an LP pool, combined with 12.5% of the supply tokens. A 1% transaction fee will be charged on every trade in the secondary market (70% goes to the project treasury, 30% goes to the protocol), forming a positive cycle of “active trading — increased research funding — advancement of results — renewed market enthusiasm.”

Incentive mechanism: Users can earn BioXP points through actions such as staking, governance voting, community promotion, and participating in newly launched projects. Points can be used to participate in the quota subscription of undervalued projects.

The implementation of these mechanisms has upgraded Bio Protocol from a “scientific research financing platform” to a “scientific research ecological operating system,” which not only addresses funding issues but also enhances the efficiency of converting research outcomes through community incentives and automation tools.

The “Long-termism” of DeSci and the Future

The market performance of BIO and the implementation of Aubrai have brought the DeSci track back into the public eye. However, the challenges in this field have never disappeared: long research cycles (even with Aubrai accelerating experiments, it still takes years for longevity therapies to move from the laboratory to clinical application), short market patience (crypto investors are used to “rapid rises and falls”), and regulatory uncertainty (the compliance costs associated with human trials are high).

In this regard, Binance founder Zhao Changpeng once stated in an interview with Foresight News: “DeSci and Meme coins are completely two extremes. DeSci projects have a long cycle, while the attention span of investors in the digital currency industry is generally short. Meme coins are very popular, and such projects are often overlooked. However, in the long run, these projects contribute greatly to humanity and society. I believe they will definitely develop in the future, though I’m uncertain about the specific timing.”